(i.e., primary care, with comorbid conditions, etc.). In recognition of the importance of dissemination, the United States Veterans Health Administration (VHA) is conducting a roll-out of PE. Yet, dissemination of additional data concerning the effectiveness of PE among veterans is needed.
The current study presents clinical treatment data on a case series (N = 10) of veterans with chronic PTSD treated with PE in a PTSD Clinic in the VHA system. The clinic hired a clinician with expertise in PE and has been training providers and implementing this treatment option for veterans. All clinical cases treated with PE between January 2006 and December 2007 with available pre-and posttreatment PTSD severity scores are presented. We hypothesize that PTSD and depressive symptoms will be reduced from pre-to posttreatment.
M E T H O D Participants and Procedure
Ten veterans (eight men, two women) diagnosed with chronic PTSD treated with PE in the PTSD Clinic (PCT) at the VA Ann Arbor Healthcare System (VAAAHS) were included. The 10 veterans averaged 39 years of age (SD = 15). Five were married, two were remarried, and three were divorced or separated. Nine of the 10 were high school graduates (of whom three had some college), and six were employed. The average service connected disability rating was roughly 30%. A majority (70%) had at least one other Axis I diagnosis. Sixty percent were prescribed at least one psychoactive medication and 40% were taking three or more psychoactive medications. All veterans had a comprehensive evaluation, including the Posttraumatic Diagnostic Scale (PDS; Foa, Cashman, Jaycox, & Perry, 1997), BDI-II scores (Beck, Steer, & Brown, 1996) , Posttraumatic Cognitions Inventory (Foa, Tolin, Ehlers, Clark, & Orsillo, 1999) , Dissociative Experiences Scale (Carlson & Putnam, 1993) , Spielberger Trait Anger Inventory (Spielberger, 1999) , Clinician Administered PTSD Scale (CAPS; Blake et al., 1995) and Mini International Neuropsychiatric Interview (MINI; Sheehan et al., 1998) . The PDS has demonstrated high internal consistency (α = .92 total) and good test-retest reliability (r = .74 to .85). The PDS contains 17 items and ranges from 0 to 51. A clinical cutoff score of 15 is used such that scores above 15 are likely to meet diagnosis of PTSD. All veterans met criteria for PTSD based on CAPS and PDS score at pretreatment (lowest PDS = 25). Means on these measures are shown in Table 1 .
Because the current analyses are from a clinical sample, formal inclusion and exclusion criteria were not utilized. Treatment plans and case assignments were made during clinic team meetings. Prolonged exposure was considered in the treatment plan for any veteran who met criteria for PTSD, was interested in receiving psychotherapy for PTSD, had at least one specific trauma memory, and did not have other clinical issues that required attention first (i.e., imminent suicidal risk, substance dependence, psychotic features, etc.). Cases that were identified as more difficult (i.e., involved significant substance use, personality disorders, recent dissociative tendencies, etc.) were assigned to the expert therapist (SR). Data presented represent all veterans with pre-and posttreatment PDS scores. Pre-and posttreatment BDI-II scores are included when available. Although additional veterans have been treated, data was not available for either pre-or posttreatment PDS. In addition, rates of dropout and data on veterans who dropped out are not available. All veterans with available data were Caucasian.
According to the MINI, 80% of the sample had at least one other Axis I diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV ; American Psychiatric Association, 1994), including current major depressive disorder (50%), bipolar disorder (20%), alcohol/drug dependence (20%), social anxiety disorder (10%), and 10% with another Axis 1 disorder. Medication was observed and recorded, but was managed irrespective of PE. At the time of PE initiation, 70% of veterans were prescribed at least one psychoactive medication. Fifty percent were prescribed at least three psychoactive medications and 20% were prescribed four or more psychoactive medications. Of those veterans on medication over the course of PE, three veterans had medication increases, one veteran discontinued medication, and three veterans had no change to medication.
The first author trained all of the clinical staff. Half of the cases (n = 5) served as first training cases for therapists with no previous experience with PE and minimal cognitive-behavioral therapy (CBT) training. The trainees included a psychology postdoctoral fellow (just received doctorate), an experienced Masters-level social worker (7 years in clinical practice), a Masters-level social worker who obtained her license during training, and two psychology advanced practicum students (currently working toward their doctorates). The PE training program involved four 2-hour didactic sessions covering the basic research, rationale, primary components, and role plays. The standard of training used was that each trainee was required to complete two training cases. For each case, the sessions were videotaped and viewed by the supervisor who provided written feedback and met with the therapist for 30 minutes per session. The current data include first training cases as well as cases seen by the first author.
A modification to the standard PE manual (Foa et al., 2007) written by the first author and Dr. Edna Foa was used. Sessions were reduced to 80 minutes and wording was changed to reflect the population. All veterans received between 7 and 21 sessions (M = 12.7; SD = 4.5). Variability in number of sessions is due to the therapist and/or patient deciding to end therapy due to symptom reduction (eight cases) or other factors (i.e., starting a new job and unable to attend sessions; two cases).
R E S U L T S
To examine changes in PTSD symptoms among the 10 veterans, 4 (total PDS, reexperiencing, avoidance numbing, and hyperarousal) separate dependent t tests comparing pre-and post-PDS scores were conducted (see Table 2 ). Effect size was then calculated using Cohen's d (Cohen, 1969) . Veterans demonstrated significant reductions in total PTSD symptoms from pre-(M = 36.2, SD = 8.1) to posttreatment (M = 17.2, SD = 9.2), t(9) = 4.69, p < .01, Cohen's d = 2.19. Cohen's d was large (Cohen, 1969) . Fifty percent of treated veterans had PDS scores below 15 suggesting they no longer met criteria for PTSD. To examine reliable and clinically significant change, a reliable change score criterion and clinical significance criterion were calculated for the PDS (Jacobson & Truax, 1991) . Using the normative data for the PDS (Foa et al., 1997) , change that exceeded 7.8 points is considered reliable change. In this sample, 90% of veterans demonstrated reliable reduction in PTSD from pre-to posttreatment. Using the clinical significance criterion of moving to the normal side of the point halfway between PTSD and non-PTSD normative samples, posttreatment scores below 23.4 are clinically significant. In this sample, 80% of veterans demonstrated clinically significant reduction in PTSD.
With regard to subscales, veterans demonstrated significant reductions in reexperiencing symptoms (pretreatment: M = 10.9, SD = 3.2; posttreatment: M = 4.9, SD = 4.2), t(7) = 3.42, p < .01, d = 1.60; avoidance symptoms (pretreatment: M = 13.5, SD = 4.3, to posttreatment: M = 5.9, SD = 4.3), t(7) = 3.50, p < .05, d = 1.77, and hyperarousal symptoms (pretreatment: M = 12.4, SD = 1.9; posttreatment: M = 6.0, SD = 3.51), t(7) = 4.12, p < .01, d = 2.28.
The small sample size in this study does not allow for comparison of returning veterans from Afghanistan and Iraq (RV) to other era veterans (Vietnam veterans [VV] and military sexual trauma [MST] veterans). Both groups demonstrated significant reductions from pretreatment to posttreatment, RV, t(4) = 3.60, p < .05, d = 2.42; VV/MST, t(4) = 2.90, p < .05, d = 1.93. Of note, 60% of RVs and 40% of the VV/MST had PDS scores below 15 suggesting they no longer met criteria for PTSD. Responses of the veterans are depicted in Figure 1 .
In addition to PTSD, 7 of 10 veterans had pre-and posttreatment BDI-II scores. To examine changes in depressive symptoms, a dependent t test comparing pre-and post-BDI-II scores was conducted. Veterans demonstrated significant reductions in total depressive symptoms from pre-(M = 25.9, SD = 10.0) to posttreatment (M = 13.7, SD = 8.4), t(6) = 4.07, p < .05, d = 1.31. Cohen's d was large (Cohen, 1969) .
To examine reliable and clinically significant change, a reliable change score criterion and clinical significance criterion were calculated for the BDI-II (Jacobson & Truax, 1991) . Using the normative data for the BDI-II (Beck et al., 1996) , change that exceeded 9.20 points is considered reliable change. In this sample, 40% of veterans demonstrated reliable reduction in depression from pre-to posttreatment. Using the clinical significance criterion of moving to the normal side of the point halfway between the depressed and nondepressed normative samples, posttreatment scores below 14.9 are clinically significant. In this sample, 40% of veterans demonstrated clinically significant reduction in depression from pre-to posttreatment.
Finally, to address whether trainee cases differed in outcome from the cases of the experienced PE clinician, two independent t tests were conducted with clinician status (trainee vs. experienced) as the independent variable and PDS and BDI-II scores as the dependent variables. No differences were detected, PDS, t(8) = 1.80, ns; BDI-II, t < 1.
D I S C U S S I O N
Prolonged exposure is effective in reducing the symptoms of PTSD in veterans receiving care in a VHA PTSD clinic. Reductions in symptoms were large across all three symptom clusters. Effect sizes (overall d = 2.19) are consistent with those found in randomized clinical trials with nonveteran and veteran populations. Specifically, the pre-to posttreatment within-group effect sizes found for PE in trials range from a low of .8 in a study of female veterans (Schnurr et al., 2007) to a high of 2.3 in a study of sexual assault survivors (Resick, Nishith, Weaver, Astin, & Feuer, 2002) .
Several additional points are to be noted. First, VV/MST and RVs responded well to PE. Second, trainees with limited CBT experience who received 8 hours of didactic training in PE treated 50% of the sample with excellent results. Severe comorbidities were ruled out as training cases; however, the sample still had significant comorbidity (80% met criteria for at least one other diagnosis). Although power may be an issue due to the small sample size, no differences in reduction of PTSD or depressive symptoms were detected between the experienced PE clinician and the trainees. These preliminary findings with recently trained therapists are encouraging in the context of training a larger number of therapists nationwide. Several caveats to the interpretation of these findings are warranted. First, the sample size is small. Second, these results are based on self-report data that may be subject to response bias. Third, these are clinical data collected in a VA PTSD clinic. As such, many factors were not controlled (i.e., medication, comorbidity, etc.), randomization was not possible, and attrition rates cannot be obtained. Fourth, adherence data was not collected on these cases. Although five of the cases were training cases that were viewed by the first author and detailed feedback provided to the therapist on violations of standard protocol, we do not know how precisely the therapists complied with the manual. In clinical practice as PE is rolled out, it is unlikely that trainee therapists will have adherence data beyond supervisor feedback. As such, these cases represent a real-time clinical application of PE. Finally, all of the veterans in this sample were Caucasian. This lack of racial/ethnic diversity is consistent with the clinic demographics (about 83% Caucasian), but we do not know whether these results will apply to other racial/ethnic groups.
These data support the efficacy of PE for use in VA PTSD clinics; nevertheless, many barriers remain. One significant barrier that is currently being surmounted is the limited availability of training. The VHA PE Roll Out initiative promises to provide training to hundreds of clinicians and create a national network of PE trainers and supervisors.
Clinicians often harbor concerns about using PE with many types of veterans or feel unsure about how to make a decision about whether to use PE or other alternative treatments (e.g., cognitive processing therapy, stress inoculation training, supportive contacts, or crisis management). For instance, in the work of the first author training clinicians in PE, many trainees believe that PE is not effective for survivors of multiple incident trauma, such as combat. However, several studies have supported the efficacy of PE for PTSD resulting from multiple incident trauma (Glynn et al., 1999; McDonagh et al., 2005; Schnurr et al., 2007) . Another concern voiced is that PE is less tolerable than other PTSD treatments. However, a meta-analysis of treatment dropout suggests that rates of dropout are similar for PE (20.5%) and other CBT treatments (22-27%) and medications (22-38%; Connor, Sutherland, Tupler, Malik, & Davidson, 1999; Hembree et al., 2003; Tucker et al., 2001) . Although research can provide some direction, additional studies are needed to examine how and why PE and other PTSD treatments work to improve treatment and assist clinicians in making informed decisions about treatment options.
Logistics of the VA clinic structure may impede the implementation of PE. For instance, clinician case-load expectations often do not allow for time to train in a new therapy. Further, supervision from an expert requires both trainee and supervisor time. Most VA clinics function based on a standard 60-minute clinical hour with the number of unique veterans contacted used as the metric for case load. This does not allow for longer and more frequent contacts with just a single veteran. Although these logistic issues require attention, recent VA Office of Mental Health policy changes have placed a premium on the provision of PE (as well as other treatments) to our veterans and promise to provide the resources needed to implement PE and other empirically supported treatments. This roll-out promises to result in improved treatment outcomes and potentially more efficient treatment for veterans with PTSD.
